Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorBostancıoğlu, R. Beklem
dc.contributor.authorKoparal, Ayşe Tansu
dc.contributor.authorBenkli, Kadriye
dc.date.accessioned2019-10-20T08:00:00Z
dc.date.available2019-10-20T08:00:00Z
dc.date.issued2014
dc.identifier.issn1382-6689
dc.identifier.issn1872-7077
dc.identifier.urihttps://dx.doi.org/10.1016/j.etap.2014.03.003
dc.identifier.urihttps://hdl.handle.net/11421/15900
dc.descriptionWOS: 000338598200001en_US
dc.descriptionPubMed ID: 24694919en_US
dc.description.abstractAround the world scientists try to design successful cures against still incurable diseases, especially cancers. New targets for prevention and new agents for therapy need to be identified. We synthesized novel metal complexes [Au(L1)(L2)Pt]Cl2 and [Ru(L1)2(L2)Pt]Cl2 for determining their cytotoxic and apoptotic effects. The complexes are synthesized by using 1,8-diaminonaphthalene (L1), and bis-1,4-di[([1,10]phenanthroline-5-il)aminomethyl]cyclohexane (L2) as ligands. This is the first study to examine these metals and these molecules in cancer treatment. We elucidated the effects of test compounds with embryonic rat fibroblast-like cells (F2408) and H-ras oncogene activated embryonic rat fibroblast-like cancer cells (5RP7). Results showed that our complexes are more effective than cisplatin to kill ras-transformed cells. Although the [Au(L1)(L2)Pt]Cl2 compound showed a cytotoxic potency higher than [Ru(L1)2(L2)Pt]Cl2 against cancer cells, it proved to be almost five times less effective in decreasing cell viability over healthy cells. Au(III) compound selectively targets the cancer cells but not the healthy cellsen_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey [TUBITAK-SBAG-108S206]; NOVARTISNovartis; Anadolu University, Commission of Scientific Research Projects [070304]en_US
dc.description.sponsorshipThis work was financed by a grant from the Scientific and Technological Research Council of Turkey (TUBITAK-SBAG-108S206) and NOVARTISNovartis (2007 Novartis Pharmaceutical and Medicinal Chemistry Drug Design and Development Research Support). The authors are grateful to Anadolu University, Commission of Scientific Research Projects for financial support to Project 070304. Authors also thank deeply to Assoc. Prof. Dr. Caghan Kizil (Helmholtz Association, German Center for Neurodegenerative Diseases (DZNE) Dresden, Germany) for proof-reading of the manuscript.en_US
dc.language.isoengen_US
dc.publisherElsevier Science BVen_US
dc.relation.isversionof10.1016/j.etap.2014.03.003en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAu(Iii)en_US
dc.subjectRu(Ii)en_US
dc.subjectPt(Ii)en_US
dc.subjectAntitumoral Activityen_US
dc.subjectApoptosisen_US
dc.subjectSelective Toxicityen_US
dc.titleInvestigation of the pharmacological profiles of dinuclear metal complexes as novel, potent and selective cytotoxic agents against leas-transformed cellsen_US
dc.typearticleen_US
dc.relation.journalEnvironmental Toxicology and Pharmacologyen_US
dc.contributor.departmentAnadolu Üniversitesi, Fen Fakültesi, Biyoloji Bölümüen_US
dc.identifier.volume37en_US
dc.identifier.issue3en_US
dc.identifier.startpage897en_US
dc.identifier.endpage906en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.contributor.institutionauthorKoparal, Ayşe Tansu
dc.contributor.institutionauthorBenkli, Kadriye


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster